Scripps Research added a 21-member Board of Overseers with big names from across San Diego life sciences as the organization broadens its scope, it was recently announced.
Once wedded to fundamental scientific research, Scripps Research has moved into drug discovery and development, as well as turned to genomics and digital tools.
The nonprofit’s board of directors is still intact, but the Board of Overseers brings expertise in growth areas, said Scripps Research, up until a recent rebranding known as The Scripps Research Institute.
The board includes heavyweights like Ionis CEO Stanley Crooke, Molecular Stethoscope CEO Tina Nova, Dexcom CEO Kevin Sayer and Biocom CEO Joe Panetta.
Pete Schultz, president and CEO of Scripps Research, said the new board will advise “institute leadership and its board of directors regarding academic, scientific and business strategies, as well as provide support for the institute’s philanthropic efforts.”
Click here for the full list of board members.
Scripps is among the San Diego research institutes pursuing new business models, as recently covered by the San Diego Business Journal.